888 related articles for article (PubMed ID: 2110013)
1. L-662,583 is a topically effective ocular hypotensive carbonic anhydrase inhibitor in experimental animals.
Sugrue MF; Gautheron P; Mallorga P; Nolan TE; Graham SL; Schwam H; Shepard KL; Smith RL
Br J Pharmacol; 1990 Jan; 99(1):59-64. PubMed ID: 2110013
[TBL] [Abstract][Full Text] [Related]
2. A comparison of L-671,152 and MK-927, two topically effective ocular hypotensive carbonic anhydrase inhibitors, in experimental animals.
Sugrue MF; Mallorga P; Schwam H; Baldwin JJ; Ponticello GS
Curr Eye Res; 1990 Jun; 9(6):607-15. PubMed ID: 2117519
[TBL] [Abstract][Full Text] [Related]
3. MK-927: a topically active ocular hypotensive carbonic anhydrase inhibitor.
Sugrue MF; Gautheron P; Grove J; Mallorga P; Viader MP; Schwam H; Baldwin JJ; Christy ME; Ponticello GS
J Ocul Pharmacol; 1990; 6(1):9-22. PubMed ID: 2362161
[TBL] [Abstract][Full Text] [Related]
4. A comparison between the effect of topical and systemic carbonic anhydrase inhibitors on aqueous humor secretion.
Brechue WF; Maren TH
Exp Eye Res; 1993 Jul; 57(1):67-78. PubMed ID: 8405174
[TBL] [Abstract][Full Text] [Related]
5. The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor.
Sugrue MF
J Ocul Pharmacol Ther; 1996; 12(3):363-76. PubMed ID: 8875343
[TBL] [Abstract][Full Text] [Related]
6. On the pharmacology of L-645,151: a topically effective ocular hypotensive carbonic anhydrase inhibitor.
Sugrue MF; Gautheron P; Schmitt C; Viader MP; Conquet P; Smith RL; Share NN; Stone CA
J Pharmacol Exp Ther; 1985 Feb; 232(2):534-40. PubMed ID: 3838190
[TBL] [Abstract][Full Text] [Related]
7. MK-507 (L-671,152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys.
Wang RF; Serle JB; Podos SM; Sugrue MF
Arch Ophthalmol; 1991 Sep; 109(9):1297-9. PubMed ID: 1929960
[TBL] [Abstract][Full Text] [Related]
8. Chemical and pharmacological properties of MK-927, a sulfonamide carbonic anhydrase inhibitor that lowers intraocular pressure by the topical route.
Maren TH; Bar-Ilan A; Conroy CW; Brechue WF
Exp Eye Res; 1990 Jan; 50(1):27-36. PubMed ID: 2307193
[TBL] [Abstract][Full Text] [Related]
9. The effect of MK-927, a topical carbonic anhydrase inhibitor, on IOP in glaucomatous monkeys.
Wang RF; Serle JB; Podos SM; Surgrue MF
Curr Eye Res; 1990 Feb; 9(2):163-8. PubMed ID: 2335112
[TBL] [Abstract][Full Text] [Related]
10. The ocular hypotensive effect of the topical carbonic anhydrase inhibitor L-671,152 in glaucomatous monkeys.
Wang RF; Serle JB; Podos SM; Sugrue MF
Arch Ophthalmol; 1990 Apr; 108(4):511-3. PubMed ID: 2322152
[TBL] [Abstract][Full Text] [Related]
11. Comparison of intraocular pressure lowering by topical and systemic carbonic anhydrase inhibitors in the rabbit.
Fanous MM; Challa P; Maren TH
J Ocul Pharmacol Ther; 1999 Feb; 15(1):51-7. PubMed ID: 10048347
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacological profiles of the potent carbonic anhydrase inhibitor dorzolamide hydrochloride, a topical antiglaucoma agent].
Kobayashi M; Naito K
Nihon Yakurigaku Zasshi; 2000 Jun; 115(6):323-8. PubMed ID: 10948564
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, acid-base balance and intraocular pressure effects of ethyloxaloylazolamide--a novel topically active carbonic anhydrase inhibitor.
Sharir M; Pierce WM; Chen D; Zimmerman TJ
Exp Eye Res; 1994 Jan; 58(1):107-16. PubMed ID: 8157096
[TBL] [Abstract][Full Text] [Related]
14. Preclinical studies on L-671,152, a topically effective ocular hypotensive carbonic anhydrase inhibitor.
Sugrue MF; Mallorga P; Schwam H; Baldwin JJ; Ponticello GS
Br J Pharmacol; 1989 Dec; 98 Suppl():820P. PubMed ID: 2611526
[No Abstract] [Full Text] [Related]
15. [Effect of topical carbonic anhydrase inhibitor (MK-507) on intraocular pressure of normal human eyes].
Yamazaki Y; Miyamoto S; Sawa M
Nippon Ganka Gakkai Zasshi; 1994 Mar; 98(3):293-7. PubMed ID: 8154389
[TBL] [Abstract][Full Text] [Related]
16. pH and drug ionization affects ocular pressure lowering of topical carbonic anhydrase inhibitors.
Brechue WF; Maren TH
Invest Ophthalmol Vis Sci; 1993 Jul; 34(8):2581-7. PubMed ID: 8325759
[TBL] [Abstract][Full Text] [Related]
17. Ocular penetration and hypotensive activity of the topically applied carbonic anhydrase inhibitor L-645,151.
Bar-Ilan A; Pessah NI; Maren TH
J Ocul Pharmacol; 1986; 2(2):109-20. PubMed ID: 3503100
[TBL] [Abstract][Full Text] [Related]
18. [The time required topical carbonic anhydrase inhibitor (MK-507) to take effect on intraocular pressure of normal human eyes].
Nakagami T; Yamazaki Y; Miyamoto S; Sawa M
Nippon Ganka Gakkai Zasshi; 1995 Sep; 99(9):1022-5. PubMed ID: 7484502
[TBL] [Abstract][Full Text] [Related]
19. Carbonic anhydrase inhibitors: synthesis of water-soluble, topically effective intraocular pressure lowering aromatic/heterocyclic sulfonamides containing 8-quinoline-sulfonyl moieties: is the tail more important than the ring?
Borras J; Scozzafava A; Menabuoni L; Mincione F; Briganti F; Mincione G; Supuran CT
Bioorg Med Chem; 1999 Nov; 7(11):2397-406. PubMed ID: 10632049
[TBL] [Abstract][Full Text] [Related]
20. Combination of systemic acetazolamide and topical dorzolamide in reducing intraocular pressure and aqueous humor formation.
Rosenberg LF; Krupin T; Tang LQ; Hong PH; Ruderman JM
Ophthalmology; 1998 Jan; 105(1):88-92; discussion 92-3. PubMed ID: 9442783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
